Home › Acute Biphenotypic Leukemia › New York › New York City
Acute Biphenotypic Leukemia clinical trials in New York City, NY
10 studies for Acute Biphenotypic Leukemia are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RecruitingPhase 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
RecruitingPhase 1/2
- Montefiore Medical Center, New York
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RecruitingPhase 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- and 2 more
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
RecruitingPhase 1
- Memorial Sloan- Kettering Cancer Center, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Revumenib and Mezigdomide in People With Leukemia
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center, New York
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RecruitingPhase 1
- Children's Hospital New York-Presbyterian, New York
- Memorial Sloan Kettering Cancer Center, New York
Acute Biphenotypic Leukemia trials in other cities
- Seattle, WA15 studies
- Houston, TX11 studies
- Atlanta, GA9 studies
- Durham, NC8 studies
- Memphis, TN7 studies
- Chicago, IL7 studies
- Charlotte, NC6 studies
- Baldwin Park, CA6 studies
- Philadelphia, PA6 studies
- Dallas, TX6 studies
- Aurora, CO6 studies
- Los Angeles, CA6 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.